MTOR and diabetic kidney disease: These findings are consistent with earlier studies reporting AMPK/mTOR pathway inhibition in lipopolysaccharide (LPS)-induced liver inflammation73, diabetic nephropathy, and cisplatin-induced renal injury models72,74.